Medicine and Dentistry
Adverse Event
8%
Age
7%
Association
6%
Atopic Dermatitis
8%
Biological Product
12%
Biological Therapy
6%
Bullous Pemphigoid
10%
Case Report
7%
Chemotherapeutic Agent
10%
Combination Therapy
22%
Consensus
5%
Cytokine
5%
Dermatosis
7%
Development
5%
Diagnosis
7%
Diseases
19%
Drug
10%
Dupilumab
7%
Erythema Multiforme
5%
Erythema Nodosum
7%
Experience
6%
Hidradenitis Suppurativa
8%
Immunosuppressive Treatment
5%
Inflammatory Bowel Disease
8%
Infliximab
5%
Inpatient
14%
Lesion
6%
Life
5%
Patient
100%
Prevalence
8%
Psoriasis
75%
Psoriasis Area and Severity Index
5%
Psoriasis Vulgaris
18%
Psoriatic Arthritis
14%
Pyoderma gangrenosum
6%
Quality of Life
6%
Risankizumab
5%
Serositis
5%
Skin
12%
Skin Defect
7%
Systemic Therapy
7%
Therapeutic Procedure
51%
Tildrakizumab
5%
TNF Inhibitor
6%
Toxic Epidermal Necrolysis
6%
Transplantation
9%
Tumor Necrosis Factor
10%
Tumor Necrosis Factor
9%
Woman
7%
Nursing and Health Professions
Biological Product
6%
Drug
5%
Etanercept
5%
Inpatient
12%
Ixekizumab
6%
Patient
26%
Psoriasis
25%
Psoriasis Area and Severity Index
6%
Psoriasis Vulgaris
7%
Psoriatic Arthritis
6%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
5%
Atopic Dermatitis
5%
Biological Product
6%
Diseases
6%
Drug
7%
Etanercept
6%
Prevalence
5%
Psoriasis
36%
Psoriasis Vulgaris
6%
Tumor Necrosis Factor
5%
